> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Complete Response Letter for Verrica NDA
- URL: https://www.fdaweb.com/fda-complete-response-letter-for-verrica-nda/
- Published: 2020-07-14T12:00:00.000Z
- Updated: 2026-09-14T16:21:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147192

FDA has issued a complete response letter seeking additional chemistry, manufacturing, and controls information from Verrica Pharmaceuticals for its NDA for VP-102, the company’s investigational proprietary drug/device combination to treat molluscum contagiosum. A company [notice](https://www.globenewswire.com/news-release/2020/07/14/2061754/0/en/Verrica-Pharmaceuticals-Receives-Complete-Response-Letter-from-the-FDA-for-its-New-Drug-Application-for-VP-102-for-the-Treatment-of-Molluscum-Contagiosum.html?ref=fdaweb.com) says the agency did not identify any clinical deficiencies.

Verrica says it will request a Type A meeting with FDA to discuss the issues that were described in the letter and other matters about the steps required to resubmit the NDA.

The company says VP-102 is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and also is in trials as a treatment for common warts and external genital warts.